3B Blackbio Dx Peer Comparison

BSE: 532067

₹1,405.10

₹35.80 (2.61%)

As on 23-Sep-2026 14:12IST

Market cap

₹1,210 Cr

Revenue (TTM)

₹153 Cr

P/E Ratio

21.8

P/B Ratio

4.3

Div. Yield

0.4 %

Edit

	3B Blackbio Dx	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Dhanuka Agritech
Market cap (₹ Cr)	1,210	23,155	16,955	6,884	4,391
Revenue (₹ Cr)	153	3,245	5,595	5,357	1,953
Net Profit (₹ Cr)	56.26	579.39	732.10	626.21	268.04
Net Margin (%)	31.16	17.04	12.71	11.46	13.42
RoE (%)	17.84	17.35	24.05	21.55	16.62
Price to Earnings	21.79	39.96	23.16	11.00	16.38
Price-To-Book	4.32	6.42	5.16	2.14	2.66

Income Statement (₹ Cr)

	3B Blackbio Dx	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Dhanuka Agritech
Operating Revenue	153.17	3,244.88	5,595.40	5,356.54	2,035.15
Total Income	180.56	3,400.10	5,760.60	5,464.12	2,071.26
Total Expenditure	99.71	2,559.91	4,702.50	4,309.62	1,618.54
EBITDA	53.46	684.97	892.90	1,046.92	416.61
Depreciation	6.19	67.63	116.90	346.70	55.46
EBIT	47.27	617.34	776.00	700.22	361.15
Interest	0.33	8.16	19.40	3.01	5.11
Other Income	27.39	155.22	165.20	107.59	36.10
Exceptional Items	0.00	10.82	0.00	0.00	--
Profit before Tax	74.33	775.21	921.80	804.80	392.14
Provision for Tax	18.06	195.82	189.70	178.58	95.18
Profit after Tax	56.26	579.39	732.10	626.21	296.96

	3B Blackbio Dx	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Dhanuka Agritech
Shareholder's Funds	324.38	3,389.67	2,965.70	3,136.49	1,402.72
Minority Interest	-0.74	0.06	0.00	-0.09	--
Non-Current Liabilities	9.81	110.60	166.20	257.07	48.81
Current Liabilities	36.55	969.81	2,567.50	2,386.20	348.58
Total Liabilities	295.72	3,963.28	8,418.00	4,968.67	1,800.11

	3B Blackbio Dx	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Dhanuka Agritech
Non-Current Assets	185.31	941.45	598.20	1,259.56	651.55
Current Assets	192.66	3,340.15	4,918.30	4,438.10	1,148.56
Total Assets	295.72	3,963.28	8,418.00	4,968.67	1,800.11
Total Debt*	0.31	0.00	0.00	0.00	42.18
Net Current Assets	156.12	2,370.34	2,350.80	2,051.90	799.98
Contingent Liabilities	200.71	38.68	684.90	101.31	58.42

	3B Blackbio Dx	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Dhanuka Agritech
Cash From Operating Activities	43.36	451.50	262.00	603.62	262.66
Cash Flow from Investing Activities	-33.85	-391.99	85.60	-510.06	-142.72
Cash from Financing Activities	-3.22	-67.92	-619.40	-67.93	-119.88
Net Cash Inflow / Outflow	6.29	-8.40	-271.80	25.63	0.06

	3B Blackbio Dx	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Dhanuka Agritech
ROCE (%)	26.03	25.71	25.42	16.87	29.41
ROE (%)	17.84	17.35	24.05	21.55	22.34
ROA (%)	16.70	13.73	13.38	11.92	17.58
EBIT Margin (%)	30.86	19.02	13.87	13.07	22.24
Net Margin (%)	31.16	17.04	12.71	11.46	14.34
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	15.98

	3B Blackbio Dx	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Dhanuka Agritech
Revenue Growth (%)	54.30	-3.61	-2.80	18.52	15.73
EBIT Growth (%)	-5.29	-0.95	22.55	68.35	24.92
Net Profit Growth (%)	14.74	3.86	23.56	49.11	24.20
EPS Growth (%)	13.24	2.55	23.56	49.11	25.58
Book Value Growth (%)	20.34	18.83	0.04	11.78	11.69

	3B Blackbio Dx	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Dhanuka Agritech
Price / Earnings	21.13	39.93	23.12	10.79	19.62
Price / Book Value	4.19	6.33	5.15	2.09	4.15
Dividend Yield (%)	0.37	0.28	3.98	2.00	0.15
EV/EBITDA	20.66	31.84	17.30	5.90	12.96
Market Cap (₹ Cr)	1,385.30	27,889.63	22,124.03	5,149.26	5,825.62

	3B Blackbio Dx	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Dhanuka Agritech
Debt to Equity	0.01	0.00	0.00	0.00	0.03
Short term debt to equity ratio	--	--	--	--	0.03
Current Ratio	5.27	3.44	1.92	1.86	3.29
Quick Ratio	4.77	2.65	1.08	1.39	2.15
Interest Coverage	226.91	95.97	48.52	268.73	77.72

	3B Blackbio Dx	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Dhanuka Agritech
Debtors to sales (%)	32.70	22.67	19.94	44.60	22.56
Asset Turnover	0.45	0.77	1.02	1.02	1.31
Receivable days	137.66	78.42	53.89	138.64	66.71
Inventory Days	32.48	68.73	110.11	78.83	67.59
Payable days	42.09	100.02	95.91	134.48	46.94
Cash Conversion Cycle	128.05	47.13	68.10	82.99	87.35

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.